BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Comment. The squeaking quality in a predominantly apical murmur led to a diagnosis of aortic stenosis in addition to coronary and hypertensive heart disease. The latter might have been the only ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...